Table 1.
Characteristics of participants at recruitment.
| Simvastatin group | Placebo group | |
|---|---|---|
| N | 9 | 9 |
| Age, years | 69.3 ± 7.2 | 66.4 ± 4.6 |
| Male, n (%) | 8 (88.9) | 7 (77.8) |
| BMI, kg/m2 | 30.0 ± 4.7 | 28.5 ± 6.5 |
| Smoking exposure, pack-years | 50.0 ± 33.5 | 50.4 ± 14.0 |
| GOLD A, n (%) | 4 (44.4) | 3 (33.3) |
| GOLD B, n (%) | 1 (11.1) | 1 (11.1) |
| GOLD C, n (%) | 3 (33.3) | 3 (33.3) |
| GOLD D, n (%) | 1 (11.1) | 2 (22.2) |
| Total cholesterol, mg/dL | 183.6 ± 29.2 | 197.6 ± 27.9 |
| Glycemia, mg/dL | 106.3 ± 17.9 | 107.6 ± 18.7 |
| Hemoglobin, g/dL | 14.9 ± 1.1 | 14.2 ± 1.6 |
| Comorbidities Arterial hypertension, n (%) Diabetes mellitus, n (%) |
6 (66.7) 2 (22.2) |
6 (66.7) 2 (22.2) |
| LA-β2, n (%) | 8 (88.9) | 7 (77.8) |
| LA Anticholinergic, n (%) | 7 (77.8) | 6 (66.7) |
| Inhaled corticosteroids, n (%) | 6 (66.7) | 7 (77.8) |
| SA-β2, n (%) | 4 (44.4) | 2 (22.2) |
| SA Anticholinergic, n (%) | 1 (11.1) | 2 (22.2) |
| ASA, n (%) ACEI, n (%) ARBs, n (%) Diuretics, n (%) |
2 (22.2) 2 (22.2) 2 (22.2) 2 (22.2) |
2 (22.2) 3 (33.3) 2 (22.2) 2 (22.2) |
N: number of patients; BMI: body mass index, LA: Long-acting, SA: short-acting, ASA: acetylsalicylic acid, ACEI: angiotensin converting enzyme inhibitor; ARBs angiotensin II receptor blocker.